Overexpression of podocalyxin-like protein is an independent factor of poor prognosis in colorectal cancer

British Journal of Cancer

Volumn 105, Issue 5, 2011, Pages 666-672

  Larsson, A ^a   Johansson, M E ^a   Wangefjord, S ^a   Gaber, A ^a   Nodin, B ^a   Kucharzewska, P ^b   Welinder, C ^b   Belting, M ^b   Eberhard, J ^b   Johnsson, A ^b   Uhlen M ^c,d   Jirstrom K ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c ALBANOVA UNIVERSITY CENTER   (Sweden)

^d ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

Author keywords

colorectal cancer; podocalyxin like; prognosis

Indexed keywords

FLUOROURACIL; OXALIPLATIN; PODOCALYXIN; PODOCALYXIN LIKE 1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; COLORECTAL SURGERY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INCIDENTAL FINDING; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; PROTEIN OVEREXPRESSION; TISSUE MICROARRAY; TREATMENT OUTCOME;

ADULT; AGED; CARCINOMA; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; SIALOGLYCOPROTEINS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 80052021347     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.295     Document Type: Article

References (26)

1. Berglund G, Elmstahl S, Janzon L, Larsson SA (1993) The malmo diet and cancer study. Design and feasibility. J Intern Med 233: 45-51
2. Casey G, Neville PJ, Liu X, Plummer SJ, Cicek MS, Krumroy LM, Curran AP, McGreevy MR, Catalona WJ, Klein EA, Witte JS (2006) Podocalyxin variants and risk of prostate cancer and tumor aggressiveness. Hum Mol Genet 15: 735-741 (Pubitemid 43264698)
3. Chen X, Higgins J, Cheung ST, Li R, Mason V, Montgomery K, Fan ST, van de Rijn M, So S (2004) Novel endothelial cell markers in hepatocellular carcinoma. Mod Pathol 17: 1198-1210 (Pubitemid 39312946)
4. Cheung HH, Davis AJ, Lee TL, Pang AL, Nagrani S, Rennert OM, Chan WY (2011) Methylation of an intronic region regulates miR-199a in testicular tumor malignancy. Oncogene; e-pub ahead of print 7 March 2011; doi: 10.1038/onc.2011.60
5. Doyonnas R, Kershaw DB, Duhme C, Merkens H, Chelliah S, Graf T, McNagny KM (2001) Anuria, omphalocele, and perinatal lethality in mice lacking the CD34-related protein podocalyxin. J Exp Med 194: 13-27 (Pubitemid 32660434)
6. Doyonnas R, Nielsen JS, Chelliah S, Drew E, Hara T, Miyajima A, McNagny KM (2005) Podocalyxin is a CD34-related marker of murine hematopoietic stem cells and embryonic erythroid cells. Blood 105: 4170-4178 (Pubitemid 40720759)
7. Gregoire M, Schopperle WM, DeWolf WC (1995) Distinct glycoforms of a tumor specific glycoprotein, gp200, in human testis and testicular tumors. J Urol 154: 275-277
8. Hase K, Shatney C, Johnson D, Trollope M, Vierra M (1993) Prognostic value of tumor 'budding' in patients with colorectal cancer. Dis Colon Rectum 36: 627-635 (Pubitemid 23206317)
9. Hayatsu N, Kaneko MK, Mishima K, Nishikawa R, Matsutani M, Price JE, Kato Y (2008) Podocalyxin expression in malignant astrocytic tumors. Biochem Biophys Res Commun 374: 394-398
10. He J, Liu Y, Xie X, Zhu T, Soules M, DiMeco F, Vescovi AL, Fan X, Lubman DM (2010) Identification of cell surface glycoprotein markers for glioblastoma-derived stem-like cells using a lectin microarray and LC-MS/MS approach. J Proteome Res 9: 2565-2572
11. Horvat R, Hovorka A, Dekan G, Poczewski H, Kerjaschki D (1986) Endothelial cell membranes contain podocalyxin-the major sialoprotein of visceral glomerular epithelial cells. J Cell Biol 102: 484-491 (Pubitemid 16140809)
12. Hsu YH, Lin WL, Hou YT, Pu YS, Shun CT, Chen CL, Wu YY, Chen JY, Chen TH, Jou TS (2010) Podocalyxin EBP50 ezrin molecular complex enhances the metastatic potential of renal cell carcinoma through recruiting Rac1 guanine nucleotide exchange factor ARHGEF7. Am J Pathol 176: 3050-3061
13. Ito T, Maki N, Hazeki O, Sasaki K, Nekooki M (2007) Extracellular and transmembrane region of a podocalyxin-like protein 1 fragment identified from colon cancer cell lines. Cell Biol Int 31: 1518-1524 (Pubitemid 47599982)
14. Koch LK, Zhou H, Ellinger J, Biermann K, Holler T, von Rucker A, Buttner R, Gutgemann I (2008) Stem cell marker expression in small cell lung carcinoma and developing lung tissue. Hum Pathol 39: 1597-1605
15. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4: 844-847 (Pubitemid 28331029)
16. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715 (Pubitemid 351636299)
17. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23: 9067-9072
18. Meng X, Ezzati P, Wilkins JA (2011) Requirement of podocalyxin in TGF-beta induced epithelial mesenchymal transition. PLoS ONE 6: e18715
19. Nielsen JS, Graves ML, Chelliah S, Vogl AW, Roskelley CD, McNagny KM (2007) The CD34-related molecule podocalyxin is a potent inducer of microvillus formation. PLoS One 2: e237
20. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108 (Pubitemid 40372904)
21. Ponten F, Jirstrom K, Uhlen M (2008) The Human Protein Atlas-a tool for pathology. J Pathol 216: 387-393
22. Prall F (2007) Tumour budding in colorectal carcinoma. Histopathology 50: 151-162 (Pubitemid 44953405)
23. Schopperle WM, Kershaw DB, DeWolf WC (2003) Human embryonal carcinoma tumor antigen, Gp200/GCTM-2, is podocalyxin. Biochem Biophys Res Commun 300: 285-290 (Pubitemid 38375807)
24. Somasiri A, Nielsen JS, Makretsov N, McCoy ML, Prentice L, Gilks CB, Chia SK, Gelmon KA, Kershaw DB, Huntsman DG, McNagny KM, Roskelley CD (2004) Overexpression of the anti-adhesin podocalyxin is an independent predictor of breast cancer progression. Cancer Res 64: 5068-5073 (Pubitemid 39006520)
25. Uhlen M, Bjorling E, Agaton C, Szigyarto CA, Amini B, Andersen E, Andersson AC, Angelidou P, Asplund A, Asplund C, Berglund L, Bergstrom K, Brumer H, Cerjan D, Ekstrom M, Elobeid A, Eriksson C, Fagerberg L, Falk R, Fall J, Forsberg M, Bjorklund MG, Gumbel K, Halimi A, Hallin I, Hamsten C, Hansson M, Hedhammar M, Hercules G, Kampf C, Larsson K, Lindskog M, Lodewyckx W, Lund J, Lundeberg J, Magnusson K, Malm E, Nilsson P, Odling J, Oksvold P, Olsson I, Oster E, Ottosson J, Paavilainen L, Persson A, Rimini R, Rockberg J, Runeson M, Sivertsson A, Skollermo A, Steen J, Stenvall M, Sterky F, Stromberg S, Sundberg M, Tegel H, Tourle S, Wahlund E, Walden A, Wan J, Wernerus H, Westberg J, Wester K, Wrethagen U, Xu LL, Hober S, Ponten F (2005) A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteomics 4: 1920-1932 (Pubitemid 41830186)
26. Yang J, Weinberg RA (2008) Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 14: 818-829 (Pubitemid 351757205)